In one paragraphArticle in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Denisse Arcos-MontoyaDepartamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-6509-7662 Patricia García-LópezLaboratorio de Fármaco-Oncología, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID 0000-0002-8790-770X Talia Wegman-OstroskyUnidad de Neuro-Oncología, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID 0000-0002-3207-6697 Ignacio Camacho-ArroyoUnidad de Investigación en Reproducción Humana, Instituto Nacional de Perinatología-Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0003-2978-1253 Silvia Anahí Valdés-RivesDepartamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-2104-4884 Claudia Bello-AlvarezDepartamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-6560-7976 Joaquín Manjarrez-MarmolejoLaboratorio de Fisiología de la Formación Reticular, Unidad de Investigaciones Cerebrales, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.ORCID 0000-0001-6421-9624 Marisol De La Fuente-GranadaDepartamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-6878-4265 Alejandro Ordaz-RamosDepartamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0009-0004-3090-9570 Daniela Ávila-GonzálezDepartamento de Fisiología y Desarrollo Celular, Instituto Nacional de Perinatología, Ciudad de México, Mexico City, Mexico.ORCID 0000-0003-4817-6630 Néstor Fabián DíazDepartamento de Fisiología y Desarrollo Celular, Instituto Nacional de Perinatología, Ciudad de México, Mexico City, Mexico.
Carlos Fabricio Guadarrama-RangelUnidad de Investigación en Reproducción Humana, Instituto Nacional de Perinatología-Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Andrés Mauricio Bonilla NavarreteUnidad de Neuro-Oncología, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID 0000-0002-5087-7594 Orwa AboudDepartment of Neurology and Neurosurgery, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.ORCID 0000-0002-7916-1629 David F Cantú-de-LeónUnidad de Neuro-Oncología, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID 0000-0002-0229-7931 Bernardo Cacho-DíazUnidad de Neuro-Oncología, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID 0000-0001-9289-5312 Aliesha González-ArenasDepartamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-9506-3180 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundGliomas, including glioblastomas (GB) and high-grade astrocytomas (HGA), are the most common brain tumors in adults, with poor survival rates around 15 months. Hormonal factors, particularly progesterone receptor (PR) activation, promote tumor growth. Current treatment involves surgery, radiotherapy and chemotherapy (temozolomide), but survival rates remain low. Repurposing mifepristone (MF), a contraceptive drug, shows promise for GB treatment, warranting further study.
methodsPR expression in U87, U251 and C6 cell lines were assessed using immunofluorescence and Western Blot. PR isoforms were quantified by densitometry. Progesterone (P4) and 5α-dihydroprogesterone (5α-DHP) synthesis were evaluated using LC/MS. MF's effect on cell viability was determined by IC
resultsPR was predominantly nuclear in all cell lines, with U87 showing the highest PR-B isoform levels. Only U251 synthesized 5α-DHP significantly. MF reduced viability in U251, U87 and C6 cells without affecting non-tumoral cells. Sphere formation efficiency decreased with MF treatment. In rats, MF reduced tumor volume dose-dependently. Clinically, MF improved patient survival from 165 to 588days and enhanced quality of life without severe adverse effects.
conclusionMF effectively reduces GB cell viability, sphere formation efficacy and tumor volume. These findings support further investigation of MF as a therapeutic strategy in GB treatment. PRÉCIS (CONDENSED ABSTRACT): Our research highlights the critical role PR in GB progression using
Indexed as
Brain NeoplasmsGlioblastomaMifepristoneReceptors, ProgesteroneAnimalsCell Line, TumorCell SurvivalDisease Models, AnimalFemaleHumansMalePilot ProjectsRatsMifepristoneReceptors, ProgesteroneGlioblastomagliomamifepristoneprogesteroneprogesterone receptor
Identifiers
PMID41439468
PMCPMC12758302
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390